SymBio Announces Bendamustine Hydrochloride (SyB L-0501) Launch in Taiwan
Complete the form below to unlock access to ALL audio articles.
SymBio Pharmaceuticals Limited has announced that its licensing partner, InnoPharmax, Inc. has launched bendamustine HCl (SyB L-0501) under the trade name Innomustine® in Taiwan for the treatment of chronic lymphocytic leukemia (CLL) and low-grade non-Hodgkin’s lymphoma (NHL) as monotherapy in patients.
InnoPharmax received approval of its New Drug Application (NDA) for bendamustine HCl (SyB L-0501) from the Taiwan Food and Drug Administration (TFDA) in October, 2011.
In Japan, SymBio received market approval of bendamustine HCl (SyB L-0501) under the trade name TREAKISYM® in October, 2010, and launched the drug in December for the treatment of patients with refractory/relapsed low grade non-Hodgkin’s lymphoma and mantle cell lymphoma.
Working with Eisai Co. Ltd., TREAKISYM® has achieved rapid market penetration in Japan.
SyB L-0501 is being marketed in other Asia Pacific countries after receiving market approvals in Hong Kong (December, 2009) and Singapore (January, 2010) for the treatment of patients with low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia, and in South Korea (May, 2011) for the treatment of patients with chronic lymphocytic leukemia and multiple myeloma.
Aspiring to be a leading oncology specialty Pharma in Asia Pacific, SymBio's business in key Asian markets continues to expand as it nimbly develops and commercializes SyB L-0501 in the hematology space to address the underserved medical needs of patients.
